AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01943019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Study NCT04175925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified Dose on Specified Days
Study NCT04175925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986322 Placebo
Description: Specified Dose on Specified Days
Study NCT00972296 — intervention group
Intervention type: DEVICE
Intervention: Carbon fiber ankle foot orthosis versus cast boot
Description: Relief of ankle pain and normalizing of gait using either device.
Study NCT02027428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane (Induction)
Description: 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
Study NCT04175925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famotidine
Description: Specified Dose on Specified Days
Study NCT02762747 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preperitoneal suction drainage
Description: preperitoneal suction drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
Study NCT03305380 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: As this is a patient registry, there are no interventions.
Study NCT01056601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m\^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period
Study NCT01056601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: 20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
Study NCT04022018 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive radiotherapy
Description: CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy.
Study NCT04022018 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: no adaptive radiotherapy
Description: Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients
Study NCT03791853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Light-CT
Description: Fresh specimen is trimmed into a block with a size not larger than 2.5 cm (Typically not larger than 1.5 cm). Prepared specimen is submitted to Light-CT tests. FF-OCT images are obtained to depict the structure information and DCI images are generated to collect the dynamic information of the cell and tissue. After the imaging detection, specimens are submitted for routine pathological diagnosis to obtain corresponding pathological images.
Study NCT02011347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT05289011 — intervention group
Intervention type: OTHER
Intervention: Interviews and questionnaires
Description: * Evaluation of inflammatory rheumatism~* Dietary survey~* International Physical Activity Questionnaire IPAQ~* BASDAI self-questionnaire~* Assessment of quality of life by ASQol questionnaire~* Assessment of fatigue by FACIT questionnaire~* Assessment of digestive symptoms~* Collection of demographic and general data~* Collection of treatment
Study NCT01492413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online lifestyle counseling and a fortified diet beverage
Description: The fortified diet beverage contains green tea extract (total catechin 167 mg), soluble dextrin fiber (10 g), and caffeine (100 mg).
Study NCT01375387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: 100 mg oral tablet, single dose
Study NCT01375387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 2 X 100 mg tablet
Study NCT01375387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 4 X 100mg tablet
Study NCT01375387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo 3
Description: Placebo - 3 tablets
Study NCT01375387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 4
Description: Placebo - 4 tablets
Study NCT01375387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo 2
Description: Placebo - 2 tablets
Study NCT00862446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: 1 gram/kg/day daily until on feeds
Study NCT00829231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Mildly Hepatic Impaired Subjects
Study NCT00829231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Moderately Hepatic Impaired Subjects
Study NCT00829231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Healthy Subjects
Study NCT00284661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FAST FIX
Description: Fast fix repair of a meniscal tear
Study NCT00284661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meniscal suturing
Description: standard suturing of meniscal tear
Study NCT01401868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-143
Description: experimental drug, dose escalation with 4 dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8 and 15. If either the 10 mg/kg or 20 mg/kg dose levels are not tolerable, a 7.5 mg/kg or a 15 mg/kg dose level will be evaluated. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2-days per week. Cycle 1 at the highest dose level is 3 weekly IV infusions on Days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.
Study NCT05366803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
Study NCT03465241 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: the ctDNA dynamic monitoring
Description: To detect ctDNA in patients using the second generation of high-throughput gene sequencing (NGS)
Study NCT03072615 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stiffness measurement
Description: Transient Elastopgraphy (TE) or Shear-Wave-Elastography
Study NCT03572140 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RAVS In relapsed and resistent cases
Description: assessment of RAVS in relapsed and resistant cases after sofosbuvir plus daclatasvir regimen
Study NCT01346839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contact Intervention
Description: The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
Study NCT01133054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: revascularization
Description: surgery or stenting
Study NCT03653286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMES and Run
Description: NMESIn this exercise protocol for quadriceps strengthening using NMES, the medium-frequency alternating current (1KHz with 10% of the work cycle) 4 will be used. The total daily training time is 900sec (15min), it is expected to perform 45 contractions per training, with three workouts per week for six weeks.~RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance.
Study NCT03653286 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Only Run
Description: RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance.
Study NCT02696590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.
Study NCT02696590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.
Study NCT03289442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supine position
Description: patients were positioned on their supine position to receive colonoscopy insertion
Study NCT02655315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone
Description: 15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
Study NCT02655315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the placebo twice daily morning and evening. The treatment lasts nine months
Study NCT01315873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m\^2 after bortezomib . Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not >1 x 10\^9/L and platelets are not >50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment.
Study NCT01315873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m\^2 followed by bendamustine given at 90 mg/m\^2. Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not >1 x 10\^9/L and platelets are not >50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment.
Study NCT03566563 — intervention group
Intervention type: OTHER
Intervention: Screening
Description: Patients tested positive for Hepatitis C will be referred to Hospital through the conventional health care services and by an alternative direct access method to determine if this improves linkage to care
Study NCT00003958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dactinomycin
Description: Given IV
Study NCT00003958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00003958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00003958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00003958 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT00003958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT00003958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT02027428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (Induction)
Description: 6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion
Study NCT02027428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane (Maintenance)
Description: 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, administered as standard of care
Study NCT02027428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (Maintenance)
Description: The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
Study NCT02027428 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abraxane (Induction)
Description: 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
Study NCT02027428 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin (Induction)
Description: 6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion, administered as standard of care
Study NCT02027428 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care (Maintenance)
Description: The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
Study NCT06104943 — intervention group
Intervention type: OTHER
Intervention: Heredity for cardiovascular disease
Description: First degree relatives with a diagnosis of Cardiovascular disease.
Study NCT06104943 — intervention group
Intervention type: OTHER
Intervention: Heredity for pancreatitis
Description: First degree relatives with a diagnosis of pancreatitis.
Study NCT06104943 — intervention group
Intervention type: OTHER
Intervention: Heredity for type 2 diabetes
Description: First degree relatives with a diagnosis of type 2 diabetes.
Study NCT06104943 — intervention group
Intervention type: OTHER
Intervention: Heredity for hypertriglyceridemia
Description: First degree relatives with hypertriglyceridemia
Study NCT04860180 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adrenalectomy
Study NCT04352725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: End-expiratory lung volume measurement and incremental PEEP titration
Description: * End expiratory lung volume measurement procedure according to the PEEP level set by the clinician, respecting a Vt at 6ml/kg IBW and Pplat\<28cmH2o~* incremental PEEP titration procedure in 5 steps starting from 5cmH2o up to 20cmH2o
Study NCT02871492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pritelivir 5% w/w ointment
Study NCT02871492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pritelivir ointment matching placebo
Study NCT02871492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zovirax® cream
Study NCT03847857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Porcine Fibrin Sealant (PFS)
Description: McKeown esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
Study NCT03847857 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: McKeown esophagectomy
Description: McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
Study NCT03847857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: McKeown esophagectomy
Description: McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
Study NCT01114607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 ChemoCentryx: formulation A
Description: ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.
Study NCT03447093 — intervention group
Intervention type: DRUG
Intervention: Methimazole Pill
Description: Patients who developed GD received methimazole treatment
Study NCT01114607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK: formulation B
Description: GSK1605786 formulation B will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
Study NCT03447093 — intervention group
Intervention type: DRUG
Intervention: Propylthiouracil Pill
Description: Patients who developed GD received propylthiouracil treatment
Study NCT03190694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Tablet
Study NCT01114607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK direct-fill: formulation C
Description: GSK1605786 formulation C will be an opaque Swedish orange body capsule with size 1, administered 30 minutes after standard breakfast.
Study NCT03190694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Tablet
Study NCT02921009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crosslinking using UV light of two different fluence rates
Description: The treatment of keratoconus involves the application of riboflavin followed by Ultraviolet light of differing intensities. This study will determine the effectiveness of a greater UV light fluence at a shorter treatment time than is currently utilized.
Study NCT03654287 — intervention group
Intervention type: OTHER
Intervention: Treatment
Description: The CELS way to intervene severe sepsis and refractory shock
Study NCT05697666 — intervention group
Intervention type: OTHER
Intervention: Modulation of the depth of the neuromuscular blockade
Description: Analysis of the respiratory mechanics at two times:~* Facial train of four = 0, indicating a deep neuromuscular blockade~* Facial train of four > 0, indicating a intermediate to light neuromuscular blockade
Study NCT02498574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Non-invasive brain stimulation applied to the surface of the scalp
Study NCT02498574 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Non-invasive brain stimulation applied to the surface of the scalp
Study NCT02498574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working Memory Training
Description: Cognitively challenging game played concurrently with transcranial direct-current stimulation
Study NCT02498574 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Working Memory Training
Description: Cognitively challenging game played concurrently with transcranial direct-current stimulation
Study NCT00894478 — intervention group
Intervention type: PROCEDURE
Intervention: Diffusion Tensor Imaging (DTI)
Description: MR and DTI: MRI and DTI will be done using 3.0T Philips MR scanner (Philips Medical Systems, Best, The Netherlands) using an eight channel head coil. DTI and axial 3D T1 will be performed on patients and controls.~1. DTI will be performed using single shot diffusion-weighted echo planar imaging, b=1000s/mm2 and 15 noncollinear directions (TR/TE=10,000/60 ms, slice thickness=2mm, field of view=22cm, matrix=112x112, NEX=2)~2. Axial 3D T1 (TR/TE=4.9/2.3 ms, slice thickness=1 mm, field of view = 24 cm, matrix=220x220, NEX=1) Patients will have additional sequences (axial and coronal T2, proton density and FLAIR) as part of their clinical scan
Study NCT00894478 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetoencephalography
Description: MEG will be performed using a whole-head Omega 151-channel gradiometer system (VSM MedTech, Port Coquitalam, BC, Canada). At least 15 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 625Hz, a bandpass filter of 10 to 70 Hz and a notch filter of 60 Hz.
Study NCT02279498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liprotamase
Description: oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
Study NCT01753674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TA-65
Description: TA-65 will be provided to volunteers, 2 pills per day of 8 mg each
Study NCT00003958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC
Study NCT02279498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: porcine (pig) PERT
Description: oral, enterically-coated, pancreatic replacement enzymes prepared from a porcine source
Study NCT03294070 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fimasartan plus amlodipine besylate
Description: Fimasartan 60 mg plus amlodipine besylate 5 mg or Fimasartan plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate